VRTX vs. AMGN, GILD, REGN, ALNY, BIIB, UTHR, NBIX, INCY, BMRN, and EXAS
Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry.
Vertex Pharmaceuticals vs.
Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
In the previous week, Amgen had 36 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 60 mentions for Amgen and 24 mentions for Vertex Pharmaceuticals. Amgen's average media sentiment score of 1.20 beat Vertex Pharmaceuticals' score of 0.83 indicating that Amgen is being referred to more favorably in the media.
Amgen has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Amgen currently has a consensus price target of $314.91, indicating a potential upside of 15.73%. Vertex Pharmaceuticals has a consensus price target of $490.38, indicating a potential upside of 16.20%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.
Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Amgen has a net margin of 13.00% compared to Vertex Pharmaceuticals' net margin of -4.52%. Amgen's return on equity of 168.35% beat Vertex Pharmaceuticals' return on equity.
Vertex Pharmaceuticals received 45 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.35% of users gave Vertex Pharmaceuticals an outperform vote while only 72.07% of users gave Amgen an outperform vote.
Summary
Amgen beats Vertex Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Vertex Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vertex Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRTX) was last updated on 1/20/2025 by MarketBeat.com Staff
